Bictegravir is among the better tolerated antiretrovirals. Most people take it without difficulty, and the effects that do occur are mostly mild and mostly early.
What happens in the first weeks?
Headache, nausea and diarrhoea in a minority, generally settling within two to four weeks. Taking the tablet with food helps some people even though it is not required.
What about sleep?
Insomnia, vivid or unusual dreams and difficulty getting to sleep are reported with integrase inhibitors as a class. They affect a minority and frequently settle. Taking the tablet in the morning rather than the evening helps some people, which is a simple thing to try.
What about mood?
Anxiety, irritability and low mood have been reported with this class. Rates in trials are low and real-world reporting has been somewhat higher. If your mood changes after starting, say so rather than attributing it to something else, since switching within or outside the class frequently resolves it.
Is that a reason to avoid it?
No, and it is a reason to be alert. Most people notice nothing. For those who do, the effect usually appears within the first weeks and responds to a change, so it is worth reporting early rather than enduring for months.
What about weight gain?
Reported with integrase inhibitors and more so in combination with tenofovir alafenamide, which is what this tablet contains. Part reflects a return to health after starting treatment and part appears to be a drug effect. It varies considerably between individuals.
Should that concern you?
Worth monitoring rather than worrying about in advance. If weight changes substantially, that is a legitimate reason to discuss alternatives, and there are regimens with a different profile.
What about lipids?
The tenofovir alafenamide component tends to be associated with higher cholesterol and triglycerides than the older tenofovir. Lipids are monitored routinely, and this is worth weighing for anyone with cardiovascular risk factors.
What about the kidneys?
Bictegravir raises blood creatinine slightly by blocking a transporter, without actually reducing kidney function. Clinicians expect this and a small early rise is not alarming. A continuing rise warrants investigation, since the tenofovir alafenamide component does need kidney monitoring.
What about hepatitis B?
Not a side effect of taking it but of stopping. The tablet suppresses hepatitis B through its other components, so abrupt withdrawal in someone with chronic infection can cause a liver flare. Hepatitis B status is checked before starting.
Are there rare serious reactions?
Hypersensitivity reactions have been reported rarely. Any rash with fever, blistering, peeling skin, or involvement of the mouth or eyes is an emergency. Marked abdominal pain, breathlessness or persistent vomiting warrant prompt attention.
What monitoring is there?
Blood tests every three to six months covering viral load, kidney and liver function and lipids, with weight recorded. Most changes appear on a test before anyone notices a symptom.
Should you look side effects up online?
The patient information leaflet lists everything ever reported, which makes it alarming and unhelpful for judging likelihood. A clinic pharmacist will tell you which effects are common and which matter, in about two minutes.
How long should you give it?
Four weeks is a reasonable trial for early effects, most of which settle in that window. Beyond a month, effects attributed to bictegravir are less likely to resolve on their own and more likely to warrant a change.
What is worth recording?
When something started, how long it lasts and whether anything changed at the same time. A short note is considerably more useful at an appointment than trying to reconstruct whether a symptom followed starting bictegravir or something else.
Who should you tell?
Your HIV clinic first, since they know the regimen. A GP can help with symptoms and will not usually change antiretrovirals. A clinic pharmacist is often the quickest route to an answer about whether bictegravir is the likely cause.
Are side effects a reason to stop?
Not to stop, and frequently a reason to change. Stopping leaves you untreated; switching keeps you covered. Almost every side effect discussed here has an alternative regimen that avoids it, so the conversation is worth having.